Vol. 4 No. 6 (2024): June
Reimbursement Reviews

Fidanacogene Elaparvovec (Beqvez)

Published June 7, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses fidanacogene elaparvovec (Beqvez), concentrate solution for infusion, 1 × 1013 vg/mL, IV infusion.
  • Indication : Fidanacogene elaparvovec is an AAV vector–based gene therapy indicated for the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B (congenital factor IX deficiency) who test negative for neutralizing antibodies to variant AAV serotype rh74.